Division of Urologic Surgery, Washington University School of Medicine, 4960 Children's Place, Campus Box 8242, St. Louis, MO, 63110, USA.
University of Missouri-Kansas City School of Medicine, 2411 Holmes Street, Kansas City, MO, 64108, USA.
J Robot Surg. 2023 Jun;17(3):835-840. doi: 10.1007/s11701-022-01464-z. Epub 2022 Oct 31.
Dissemination of robotic surgical technology for robot-assisted laparoscopic prostatectomy (RALP) has yielded advancements including the Retzius-sparing (RS) approach and the single-port (SP) platform. The safety and feasibility of each individual advancement have been evaluated, yet there is a lack of literature comparing SP RS-RALP to conventional multi-port (MP) RS-RALP. All patients who underwent RS-RALP at our institution between January 2019 and February 2021 were retrospectively reviewed. Data regarding baseline patient and tumor characteristics, operative characteristics, and surgical outcomes were collected and analyzed using the Fisher's exact test and two-tailed unpaired t tests. 62 patients were evaluated: 31 received SP RS-RALP and 31 received MP RS-RALP. Differences in patient age, BMI, and initial PSA were not observed. Lower median lymph node yield (SP: 4 vs MP: 12, p < 0.01), lower estimated blood loss (SP: 111.2 vs. MP 157.8 mL, p < 0.01), shorter operative time (SP: 207.7 vs. MP: 255.9 min, p < 0.01) and decreased length of stay (SP: 0.39 vs. MP: 1.23 days, p < 0.01) were observed in the SP RS-RALP cohort. No differences in positive surgical margins, complications, or biochemical recurrence rates were observed. SP RS-RALP is non-inferior to MP RS-RALP in terms of both perioperative and early oncologic outcomes. Despite the small sample size, the SP platform is a safe and feasible option for RS-RALP and confers potential benefits in the form of shorter operative time and reduced length of stay.
机器人辅助腹腔镜前列腺切除术(RALP)中机器人手术技术的传播带来了一些进展,包括保留耻骨后间隙(Retzius-sparing,RS)入路和单端口(single-port,SP)平台。已经评估了每种方法的安全性和可行性,但缺乏比较 SP RS-RALP 与传统多端口(multi-port,MP)RS-RALP 的文献。我们回顾性分析了 2019 年 1 月至 2021 年 2 月在我院接受 RS-RALP 的所有患者。收集并分析了患者和肿瘤特征、手术特点和手术结果的数据,使用 Fisher 确切检验和双侧非配对 t 检验进行分析。共评估了 62 例患者:31 例接受 SP RS-RALP,31 例接受 MP RS-RALP。患者年龄、BMI 和初始 PSA 无差异。SP 组淋巴结采集中位数较低(SP:4 枚 vs. MP:12 枚,p<0.01),估计出血量较少(SP:111.2 毫升 vs. MP:157.8 毫升,p<0.01),手术时间较短(SP:207.7 分钟 vs. MP:255.9 分钟,p<0.01),住院时间较短(SP:0.39 天 vs. MP:1.23 天,p<0.01)。SP RS-RALP 组和 MP RS-RALP 组在切缘阳性率、并发症和生化复发率方面无差异。SP RS-RALP 在围手术期和早期肿瘤学结果方面与 MP RS-RALP 相当。尽管样本量较小,但 SP 平台是 RS-RALP 的一种安全且可行的选择,在缩短手术时间和减少住院时间方面具有潜在优势。